Verrica Pharmaceuticals Inc (VRCA) - Total Liabilities

Latest as of March 2026: $22.73 Million USD

Based on the latest financial reports, Verrica Pharmaceuticals Inc (VRCA) has total liabilities worth $22.73 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Verrica Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.

Verrica Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)

This chart illustrates how Verrica Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See VRCA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Verrica Pharmaceuticals Inc Competitors by Total Liabilities

The table below lists competitors of Verrica Pharmaceuticals Inc ranked by their total liabilities.

Company	Country	Total Liabilities
ChampionsGate Acquisition Corporation Class A Ordinary Share NASDAQ:CHPG	USA	$1.62 Million
BIOCELTIX S.A. ZY -10 F:XI3	Germany	€2.36 Million
Quick Heal Technologies Limited NSE:QUICKHEAL	India	Rs1.10 Billion
Maeil Holdings Co. Ltd KQ:005990	Korea	₩567.53 Billion
W5 Solutions AB ST:W5	Sweden	Skr285.28 Million
CURATIS N AG SW:CURN	Switzerland	CHF9.96 Million
Real Estate & E-Commerce Split Corp TO:RS	Canada	CA$121.73 Million
Cavatina Holding S.A. WAR:CAV	Poland	zł2.84 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Verrica Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VRCA stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.02	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.59	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Verrica Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Verrica Pharmaceuticals Inc (2016–2025)

The table below shows the annual total liabilities of Verrica Pharmaceuticals Inc from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	$22.39 Million	-65.02%
2024-12-31	$63.99 Million	+3.49%
2023-12-31	$61.83 Million	+1218.98%
2022-12-31	$4.69 Million	-90.13%
2021-12-31	$47.52 Million	+15.43%
2020-12-31	$41.17 Million	+1107.63%
2019-12-31	$3.41 Million	+37.63%
2018-12-31	$2.48 Million	-84.64%
2017-12-31	$16.12 Million	+402.62%
2016-12-31	$3.21 Million	--

About Verrica Pharmaceuticals Inc

NASDAQ:VRCA USA Biotechnology

Market Cap

$89.67 Million

Market Cap Rank

#19513 Global

#4416 in USA

Share Price

$5.22

Change (1 day)

-0.76%

52-Week Range

$3.28 - $9.10

All Time High

$20.34